- Academic Editors
-
-
-
Announcements
Open Access
Review
Management of Cardiovascular Diseases in Chronic Hemodialysis Patients
Zhen Zhang1,2,3,4, Yaqiong Wang1,2,3,4,*
Show Less
1
Department of Nephrology, Zhongshan Hospital, Fudan University, 200032 Shanghai, China
2
Shanghai Medical Center for Kidney Disease, Shanghai Municipal Health Commission, 200032 Shanghai, China
3
Shanghai Institute of Kidney and Dialysis, 200032 Shanghai, China
4
Hemodialysis Quality Control Center of Shanghai, Shanghai Medical Quality Control Management Center, 200032 Shanghai, China
*Correspondence: wang.yaqiong@zs-hospital.sh.cn (Yaqiong Wang)
Rev. Cardiovasc. Med. 2023, 24(7), 185;
https://doi.org/10.31083/j.rcm2407185
Submitted: 29 October 2022 | Revised: 1 February 2023 | Accepted: 23 February 2023 | Published: 29 June 2023
(This article belongs to the Special Issue Coronary Artery Disease in Dialysis Patients)
Copyright: © 2023 The Author(s). Published by IMR Press.
This is an open access article under the CC BY 4.0 license.
Abstract
Hemodialysis (HD) is the main treatment modality for patients with end-stage kidney disease. Cardiovascular diseases (CVD) are highly prevalent in HD patients and are the leading cause of death in this population, with the mortality from CVD approximately 20 times higher than that of the general population. Traditional and non-traditional cardiovascular risk factors accelerate progression of CVD and exacerbate the prognosis in HD patients. This review provides a brief overview of the characteristics of CVD in HD patients, and a description of advances in its management.
Keywords
hemodialysis
end-stage kidney disease
cardiovascular disease
Funding
82104617/National Science Foundation of China
81871598/National Science Foundation of China
SHDC12018127/Shanghai ShenKang Hospital Development Center
Figures
Fig. 1.